Mitosis as an anti-cancer drug target

Anne-Leena Salmela, Marko Kallio (Corresponding Author)

Research output: Contribution to journalArticleScientificpeer-review

36 Citations (Scopus)

Abstract

Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.
Original languageEnglish
Pages (from-to)431-449
JournalChromosoma
Volume122
Issue number5
DOIs
Publication statusPublished - 2013
MoE publication typeA1 Journal article-refereed

Fingerprint

Mitosis
Aurora Kinases
Pharmaceutical Preparations
Neoplasms
Microtubules
Cell Proliferation
Drug Therapy

Keywords

  • anti-mitotics
  • cancer
  • drug development
  • LMW inhibitors
  • mitosis

Cite this

Salmela, Anne-Leena ; Kallio, Marko. / Mitosis as an anti-cancer drug target. In: Chromosoma. 2013 ; Vol. 122, No. 5. pp. 431-449.
@article{b749870bcdfd4ed8a07da259fd871f28,
title = "Mitosis as an anti-cancer drug target",
abstract = "Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.",
keywords = "anti-mitotics, cancer, drug development, LMW inhibitors, mitosis",
author = "Anne-Leena Salmela and Marko Kallio",
year = "2013",
doi = "10.1007/s00412-013-0419-8",
language = "English",
volume = "122",
pages = "431--449",
journal = "Chromosoma",
issn = "0009-5915",
publisher = "Springer",
number = "5",

}

Salmela, A-L & Kallio, M 2013, 'Mitosis as an anti-cancer drug target', Chromosoma, vol. 122, no. 5, pp. 431-449. https://doi.org/10.1007/s00412-013-0419-8

Mitosis as an anti-cancer drug target. / Salmela, Anne-Leena; Kallio, Marko (Corresponding Author).

In: Chromosoma, Vol. 122, No. 5, 2013, p. 431-449.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Mitosis as an anti-cancer drug target

AU - Salmela, Anne-Leena

AU - Kallio, Marko

PY - 2013

Y1 - 2013

N2 - Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.

AB - Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.

KW - anti-mitotics

KW - cancer

KW - drug development

KW - LMW inhibitors

KW - mitosis

U2 - 10.1007/s00412-013-0419-8

DO - 10.1007/s00412-013-0419-8

M3 - Article

VL - 122

SP - 431

EP - 449

JO - Chromosoma

JF - Chromosoma

SN - 0009-5915

IS - 5

ER -